Printer Friendly

IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER TO VICE PRESIDENT, FINANCE AND ADMINISTRATION

 IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER
 TO VICE PRESIDENT, FINANCE AND ADMINISTRATION
 LA JOLLA and MOUNTAIN VIEW, Calif., Nov. 20 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH), a leader in the development of immunologically active monoclonal antibodies for therapeutic applications, has promoted Phillip M. Schneider to the newly created position of vice president, finance and administration.
 Schneider, 35, joined IDEC Pharmaceuticals in 1987 as director, finance and administration and has been senior director, finance and administration since 1990. From 1984 to 1987, Mr. Schneider served as the manager of financial reporting and as a senior analyst for Syntex Laboratories. He earned his C.P.A. while working for KPMG Peat Marwick as a senior accountant from 1982 to 1984 and received his Masters of Business Administration from the University of Southern California in 1982. From 1978 to 1980, Mr. Schneider was a senior research associate at Cutter Laboratories. He earned his Bachelor of Science degree in biochemistry at the University of California at Davis in 1978.
 "Mr. Schneider's promotion to vice president is in recognition of his contributions toward building IDEC's finance and administration functions," said Dr. William H. Rastetter, IDEC's president and chief executive officer. "Mr. Schneider has played a significant role in our company's financing activities, including several private placements, and our recently completed initial public offering of common stock," Rastetter commented.
 IDEC Pharmaceuticals Corporation, with facilities in La Jolla and Mountain View, has four products in ongoing human clinical studies and other products in preclinical testing and research and development. The company's products are intended to address severe or life threatening diseases including immune system cancers (lymphomas and leukemias), malignant melanoma, HIV infection and autoimmune disorders.
 -0- 11/20/91
 /CONTACT: William H. Rastetter, president and CEO of IDEC Pharmaceuticals, 619-458-0600/
 (IDPH) CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER


SE-EH -- SD002 -- 5355 11/20/91 10:57 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:312
Previous Article:ATC ENVIRONMENTAL TERMINATES NEGOTIATIONS TO ACQUIRE TEXAS COMPANY
Next Article:GRANDMET MAKES L359 MILLION DAIRY DISPOSAL
Topics:


Related Articles
KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS
NABIL HANNA PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND PRECLINCIAL DEVELOPMENT AT IDEC PHARMACEUTICALS
WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT
DAVID LUDVIGSON JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
KENNETH WOOLCOTT PROMOTED TO VICE PRESIDENT, GENERAL COUNSEL & LICENSING EXECUTIVE OF IDEC PHARMACEUTICALS
IDEC PHARMACEUTICALS APPOINTS PHILLIP SCHNEIDER CHIEF FINANCIAL OFFICER
IDEC PHARMACEUTICALS PROMOTES ANTONIO J. GRILLO-LOPEZ TO SENIOR VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
JOHN GEIGERT JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, QUALITY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters